Not checkedNot checked for notices yet.
Relationship between methotrexate dose and clinical efficacy for treatment of rheumatoid arthritis
HE Longquan, SHI Ying, ZOU Qinghua and 3 more
Di-san junyi daxue xuebao · 2020
doi:10.16016/j.1000-5404.202003380 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Objective To study the relation of methotrexate (MTX) dose with blood concentration of MTX polyglutamates (MTX-PGs) and clinical efficacy and explore the optimal initial dose of MTX for treatment of rheumatoid arthritis (RA). Methods We conducted a retrospective analysis of 165 RA patients receiving treatment in our hospital with MTX at the weekly oral dose of 10(n=67), 12.5(n=66) or 15 mg (n=32). The 28 joint disease activity scores (DAS28) were calculated before and after 8 weeks of MTX treatment. According to the European Union Anti-rheumatic Union (EULAR) criteria for efficacy evaluation, the clinical efficacy of the treatment was categorized into favorable responses (including significant and moderate responses) and nonresponse. High-performance liquid chromatography/tandem mass spectrometry (HPLC/MS/MS) assay was used to determine the blood concentration of MTX-PGs of the patients, and relations of MTX dose with the clinical efficacy, DAS28 after treatment and blood MTX-PGs concentration was analyzed. Results The patients taking MTX at the weekly dose of 10, 12.5 and 15 mg showed total response rates of 37.31%, 57.58%, and 56.25%, respectively, which was significantly lower in 10 mg group than in 12.5 mg group (P < 0.05). The median DAS28 after treatment was 3.92 (2.13-5.15), 2.80 (1.81-4.22), and 2.96 (2.26-3.67) in the 10, 12.5, and 15 mg groups, respectively, significantly higher in the 10 mg group than in 12.5 mg group (P < 0.05). The median blood concentrations of MTX-PGs in the 10, 12.5, and 15 mg groups were 92.0 (88.0-96.0), 112.0 (103.0-115.0), and 127.5 ng/mL (102.0-153.8 ng/mL), respectively, showing significant differences among the 3 dose groups (P < 0.05). An increased MTX dose was associated with a higher MTX-PGs concentration in these patients. In 10 mg group, the mean blood concentration of MTX-PGs was 92.5±7.0 ng/mL, significantly lower than the documented concentration (92.5±7.0 ng/mL) required to produce a clinical response (P < 0.05). Conclusion MTX at the weekly oral dose of 12.5 mg can be the optimal initial dose for treatment of local RA patients in Chongqing.
Abstract licence: CC BY
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.